Elevance Health (ELV) FY2025 results: revenue $199.1 billion, up 12.5% on the year
Elevance Health, Inc. (ELV) reported revenue of $199.1 billion for fiscal 2025, the year ended 31 December 2025, up 12.5% on the year before. Net income was $5.7 billion, down 5.3%, and diluted earnings per share $25.21. The figures are the company's own, from the 10-K it filed with the SEC on 6 February 2026.
this yearthe year beforeHover a bar for its figure.
The year in brief
What management said about the year
Guidance figures: 22 new.
- Revenue rose 10 percent in quarter: Operating revenue was $49.3 billion in the fourth quarter, up 10 percent, driven by higher premium yields, acquisitions and Medicare Advantage growth, partly offset by Medicaid attrition.
- Quarterly and annual EPS figures reported: Fourth quarter diluted EPS was $2.47 against $1.81, and adjusted diluted EPS was $3.33 against $3.23. Full year diluted EPS was $25.21 and adjusted diluted EPS $30.29, against $33.04.
- Health Benefits swung to adjusted loss: Health Benefits reported an adjusted operating loss of $0.2 billion in the fourth quarter and an adjusted operating gain of $4.2 billion for the year. Both periods were affected mainly by higher medical cost trend.
- Medical membership down 1 percent: Medical membership was about 45.2 million at December 31, 2025, down 0.5 million, driven by Medicaid attrition. Medicare Advantage membership rose 7.9 percent to 2.23 million.
- Cost trend in ACA and Part D: The fourth quarter benefit expense ratio of 93.5 percent rose 110 basis points, reflecting higher medical cost trend in ACA health plans and Medicare Part D seasonality from Inflation Reduction Act changes.
From this 10-K
Elevance Health sells health cover and health services. It served approximately 45.2 million medical members through its affiliated health plans at the end of 2025, and describes itself as one of the largest health insurers in the United States by medical membership. Its position rests on something structural: it is an independent licensee of the Blue Cross and Blue Shield Association, which gives it the Blue brands in a defined list of states.
The four quarters: Q1 FY2025 · Q2 FY2025 · Q3 FY2025 · Q4 FY2025
Income statement (profit and loss)
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Revenue | 199,125 | 177,011 | 171,340 | +12.5% | |
| Cost of revenue | 21,178 | 19,750 | 17,293 | +7.2% | |
| Gross profit | 177,947 | 157,261 | 154,047 | +13.2% | |
| Gross margin | 89.4% | 88.8% | 89.9% | ||
| Selling, general and administrative | 20,984 | 20,025 | 20,087 | +4.8% | |
| Operating income | 7,199 | 7,862 | 8,499 | -8.4% | |
| Operating margin | 3.6% | 4.4% | 5.0% | ||
| Interest expense | 1,402 | 1,185 | 1,030 | +18.3% | |
| Pre-tax income | 6,710 | 7,904 | 7,715 | -15.1% | |
| Income tax | 1,049 | 1,933 | 1,724 | -45.7% | |
| Effective tax rate | 15.6% | 24.5% | 22.3% | ||
| Net income | 5,662 | 5,980 | 5,987 | -5.3% | |
| Net margin | 2.8% | 3.4% | 3.5% | ||
| Diluted EPS | $25.21 | $25.68 | $25.22 | -1.8% |
Read more
Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.Cash flow
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Operating cash flow | 4,290 | 5,808 | 8,061 | -26.1% | |
| Capital expenditure | 1,116 | 1,256 | 1,296 | -11.1% | |
| Free cash flow | 3,174 | 4,552 | 6,765 | -30.3% | |
| Free cash flow margin | 1.6% | 2.6% | 3.9% | ||
| Cash from investing | -1,344 | -5,167 | -5,572 | ||
| Cash from financing | -1,738 | 1,193 | -3,349 | ||
| Depreciation and amortisation | 1,546 | 1,393 | 1,745 | +11.0% | |
| Share-based compensation | 276 | 191 | 289 | +44.5% | |
| Buybacks | 2,605 | 2,900 | 2,676 | -10.2% | |
| Dividends paid | 1,529 | 1,508 | 1,395 | +1.4% | |
| Dividend per share | n/a | n/a | $5.92 | ||
| Diluted shares, weighted | 225m | 233m | 237m | -3.6% | |
| Shares outstanding at period end | 221m | 227m | 233m | -3.0% |
Balance sheet
| $ million | FY2025 | FY2024 | FY2023 | On the year | Last 8 years |
|---|---|---|---|---|---|
| Shareholders' equity | 43,882 | 41,315 | 39,306 | +6.2% | |
| Non-controlling interest | 144 | 111 | 99.0 | +29.7% | |
| Short-term borrowings | 150 | n/a | n/a | ||
| Debt | 31,896 | 31,232 | 25,120 | +2.1% | |
| Operating lease liabilities | 529 | 658 | 685 | -19.6% | |
| Other liabilities | 44,893 | 43,573 | 43,718 | +3.0% | |
| Total liabilities and equity | 121,494 | 116,889 | 108,928 | +3.9% | |
| Fixed assets | 4,679 | 4,652 | 4,359 | +0.6% | |
| Goodwill | 28,344 | 28,277 | 25,317 | +0.2% | |
| Intangible assets | 11,200 | 12,094 | 10,273 | -7.4% | |
| Investments | 27,005 | 26,236 | 30,490 | +2.9% | |
| Cash and equivalents | 9,491 | 8,288 | 6,526 | +14.5% | |
| Other assets | 40,775 | 37,342 | 31,963 | +9.2% | |
| Total assets | 121,494 | 116,889 | 108,928 | +3.9% |
10-K for the year ended 31 December 2025, filed 6 February 2026: the filing.